Sucralfate | CAS# 54182-58-0 | Gastroprotectant

MedKoo Cat#: 574194 | Name: Sucralfate

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Sucralfate is a basic aluminum sucrose sulfate complex that has gastroprotective activity. It inhibits pepsin and ulcer formation induced by pyloric ligation, indomethacin, or cysteamine. Sucralfate is protective against neutral ethanol and acidified taurocholic acid-induced damage. Formulations containing sucralfate have been used as antacids in the treatment of duodenal ulcer.

Chemical Structure

Sucralfate

CAS#54182-58-0

Theoretical Analysis

MedKoo Cat#: 574194

Name: Sucralfate

CAS#: 54182-58-0

Chemical Formula: C12H54Al16O75S8

Exact Mass: 2085.5223

Molecular Weight: 2086.67

Elemental Analysis: C, 6.91; H, 2.61; Al, 20.69; O, 57.50; S, 12.29

Price and Availability

Size	Price	Availability	Quantity
500mg	USD 205.00
1g	USD 340.00

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Sucralfate

IUPAC/Chemical Name

hexadeca-μ-hydroxytetracosahydroxy[μ8-[[1,3,4,6-tetra-O-sulfo-β-D-fructofuranosyl α-D-glucopyranoside tetrakis(sulfato-κO')](8-)]]hexadeca-aluminum

InChi Key

DTULOKYBGCTCFP-QRLOXDDHSA-A

InChi Code

InChI=1S/C12H22O35S8.16Al.40H2O/c13-48(14,15)37-1-4-6(43-51(22,23)24)8(45-53(28,29)30)9(46-54(31,32)33)11(40-4)42-12(3-39-50(19,20)21)10(47-55(34,35)36)7(44-52(25,26)27)5(41-12)2-38-49(16,17)18;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;/h4-11H,1-3H2,(H,13,14,15)(H,16,17,18)(H,19,20,21)(H,22,23,24)(H,25,26,27)(H,28,29,30)(H,31,32,33)(H,34,35,36);;;;;;;;;;;;;;;;;40*1H2/q;16*+3;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;/p-48/t4-,5-,6-,7-,8+,9-,10+,11-,12+;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;/m1......................................................../s1

SMILES Code

O=S(OC[C@@H]1[C@@H](OS(=O)([O-][Al+3]2([OH-][Al+3]([OH-])([OH-])[OH-]2)[OH-])=O)[C@H](OS(=O)([O-][Al+3]3([OH-][Al+3]([OH-])([OH-])[OH-]3)[OH-])=O)[C@](COS(=O)([O-][Al+3]4([OH-][Al+3]([OH-])([OH-])[OH-]4)[OH-])=O)(O[C@@]5([H])O[C@H](COS(=O)([O-][Al+3]6([OH-][Al+3]([OH-])([OH-])[OH-]6)[OH-])=O)[C@@H](OS(=O)([O-][Al+3]7([OH-][Al+3]([OH-])([OH-])[OH-]7)[OH-])=O)[C@H](OS(=O)([O-][Al+3]8([OH-][Al+3]([OH-])([OH-])[OH-]8)[OH-])=O)[C@H]5OS(=O)([O-][Al+3]9([OH-][Al+3]([OH-])([OH-])[OH-]9)[OH-])=O)O1)([O-][Al+3]%10([OH-][Al+3]([OH-])([OH-])[OH-]%10)[OH-])=O

Appearance

Solid powder

Purity

>95% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

Sucralfate inhibits peptic activity and binds to negatively charged subepithelial proteins exposed during mucosal injury, forming a viscous layer that protects the vascular bed and proliferative zone.

In vitro activity:

Sucralfate may be of clinical relevance in the treatment of bleeding peptic ulcers. Native gastric juice completely digested the in vitro blood clots, while in neutralized gastric juice or in gastric juice containing antacids or sucralfate no digestion was seen. In the second experiment, native gastric juice completely digested all remaining clots, except those previously exposed to sucralfate. Gastric juice containing 3% or more of sucralfate had this long-lasting, clot-protective effect. Reference: Digestion. 2006;73(2-3):198-203. https://pubmed.ncbi.nlm.nih.gov/16837806/

In vivo activity:

Sucralfate suspension oral rinse can be recommended as an effective topical analgesic solution in postoperative secondary healing of intraoral wounds with no significant interference. The mean change of VAS score was significantly lower from baseline in the sucralfate group on day 3 and day 7. Wound grade distribution over time was the same in sucralfate and control groups. The mean change in wound length was not significantly different between the two groups. No adverse reactions to sucralfate were reported. Reference: Laryngoscope Investig Otolaryngol. 2023 Aug 24;8(5):1226-1232. https://pubmed.ncbi.nlm.nih.gov/37899873/

Preparing Stock Solutions

The following data is based on the product molecular weight 2,086.67 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Nysaeter G, Berstad A. Sucralfate protects blood clots from peptic digestion by gastric juice in vitro. Digestion. 2006;73(2-3):198-203. doi: 10.1159/000094529. Epub 2006 Jul 11. PMID: 16837806. 2. Miyake K, Tsukui T, Shinji Y, Shinoki K, Hiratsuka T, Nishigaki H, Futagami S, Wada K, Gudis K, Iwakiri K, Yamada N, Sakamoto C. Teprenone, but not H2-receptor blocker or sucralfate, suppresses corpus Helicobacter pylori colonization and gastritis in humans: teprenone inhibition of H. pylori-induced interleukin-8 in MKN28 gastric epithelial cell lines. Helicobacter. 2004 Apr;9(2):130-7. doi: 10.1111/j.1083-4389.2004.00209.x. PMID: 15068414. 3. Suparakchinda C, Rawangban W. Effectiveness of Sucralfate comparing to normal saline as an oral rinse in pain reduction and wound healing promotion in oral surgery. Laryngoscope Investig Otolaryngol. 2023 Aug 24;8(5):1226-1232. doi: 10.1002/lio2.1146. PMID: 37899873; PMCID: PMC10601550. 4. Watanabe K, Murakami K, Sato R, Kashimura K, Miura M, Ootsu S, Miyajima H, Nasu M, Okimoto T, Kodama M, Fujioka T. Effect of sucralfate on antibiotic therapy for Helicobacter pylori infection in mice. Antimicrob Agents Chemother. 2004 Dec;48(12):4582-8. doi: 10.1128/AAC.48.12.4582-4588.2004. PMID: 15561829; PMCID: PMC529215.

In vitro protocol:

In vivo protocol:

1. Suparakchinda C, Rawangban W. Effectiveness of Sucralfate comparing to normal saline as an oral rinse in pain reduction and wound healing promotion in oral surgery. Laryngoscope Investig Otolaryngol. 2023 Aug 24;8(5):1226-1232. doi: 10.1002/lio2.1146. PMID: 37899873; PMCID: PMC10601550. 2. Watanabe K, Murakami K, Sato R, Kashimura K, Miura M, Ootsu S, Miyajima H, Nasu M, Okimoto T, Kodama M, Fujioka T. Effect of sucralfate on antibiotic therapy for Helicobacter pylori infection in mice. Antimicrob Agents Chemother. 2004 Dec;48(12):4582-8. doi: 10.1128/AAC.48.12.4582-4588.2004. PMID: 15561829; PMCID: PMC529215.

1. Borella, L.E., Seethaler, K., and Lippmann, W. Sucralfate: Antipeptic, antiulcer activities and antagonism of gastric emptying. Arzneimittelforschung 29(5), 793-798 (1979). 2. Harrington, S.J., Schlegel, J.F., and Code, C.F. The protective effect of sucralfate on the gastric mucosa of rats. J. Clin. Gastroenterol. 3(Suppl 2), 129-134 (1981).